Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neoprobe changes name to Navidea

This article was originally published in Clinica

Executive Summary

Dublin, Ohio-based radiotracer developer Neoprobe has changed its name to Navidea Biopharmaceuticals – a play on the words "navigating ideas". The company said it represents it dedication to "translate cutting edge innovation and precision diagnostics technology into novel products to advance patient care". Also this month, former president and CEO David Bupp retired from his role as director. The moves appear to be part of the firm's strategy of focusing on its lead products, the radiopharmaceutical agents Lymphoseek and RIGScan, which started in May when it sold off its line of gamma detection devices to Devicor Medical Products (www.clinica.co.uk, 26 May 2011).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel